Cargando…

Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report

Moxifloxacin is a rare but important cause of drug-induced immune thrombocytopenia (DIT). We describe a patient who presented with an acute onset of severe thrombocytopenia complicated by petechial rash, epistaxis, and melena. Recent new drug exposures included moxifloxacin and two proton pump inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Joel, Baer, Maria R, Grover, Brian E, Aster, Richard H, Millstein, Leah S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571590/
https://www.ncbi.nlm.nih.gov/pubmed/33094048
http://dx.doi.org/10.7759/cureus.10507
_version_ 1783597198784593920
author Moore, Joel
Baer, Maria R
Grover, Brian E
Aster, Richard H
Millstein, Leah S
author_facet Moore, Joel
Baer, Maria R
Grover, Brian E
Aster, Richard H
Millstein, Leah S
author_sort Moore, Joel
collection PubMed
description Moxifloxacin is a rare but important cause of drug-induced immune thrombocytopenia (DIT). We describe a patient who presented with an acute onset of severe thrombocytopenia complicated by petechial rash, epistaxis, and melena. Recent new drug exposures included moxifloxacin and two proton pump inhibitors. On presentation to the hospital, all recently initiated medications were discontinued and the patient’s thrombocytopenia was treated with platelet transfusions, intravenous immunoglobulin, and high-dose corticosteroids. Her thrombocytopenia improved over the next seven days and she was discharged on hospital day 8. Serologic testing revealed strongly positive moxifloxacin-dependent IgM and IgG antiplatelet antibodies, confirming a diagnosis of moxifloxacin-induced immune thrombocytopenia. DIT has been reported with other fluoroquinolone antibiotics, especially ciprofloxacin. This case documents a rare but potentially fatal complication of exposure to moxifloxacin and is the first to demonstrate objective evidence of acute sensitization with IgM antibody positivity. It highlights the need to consider this potential reaction when choosing antibiotic therapy, particularly in patients who are at high risk for bleeding, have hematologic disorders, or are receiving myelosuppressive therapies, and perhaps in those with a history of multiple drug allergies.
format Online
Article
Text
id pubmed-7571590
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-75715902020-10-21 Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report Moore, Joel Baer, Maria R Grover, Brian E Aster, Richard H Millstein, Leah S Cureus Internal Medicine Moxifloxacin is a rare but important cause of drug-induced immune thrombocytopenia (DIT). We describe a patient who presented with an acute onset of severe thrombocytopenia complicated by petechial rash, epistaxis, and melena. Recent new drug exposures included moxifloxacin and two proton pump inhibitors. On presentation to the hospital, all recently initiated medications were discontinued and the patient’s thrombocytopenia was treated with platelet transfusions, intravenous immunoglobulin, and high-dose corticosteroids. Her thrombocytopenia improved over the next seven days and she was discharged on hospital day 8. Serologic testing revealed strongly positive moxifloxacin-dependent IgM and IgG antiplatelet antibodies, confirming a diagnosis of moxifloxacin-induced immune thrombocytopenia. DIT has been reported with other fluoroquinolone antibiotics, especially ciprofloxacin. This case documents a rare but potentially fatal complication of exposure to moxifloxacin and is the first to demonstrate objective evidence of acute sensitization with IgM antibody positivity. It highlights the need to consider this potential reaction when choosing antibiotic therapy, particularly in patients who are at high risk for bleeding, have hematologic disorders, or are receiving myelosuppressive therapies, and perhaps in those with a history of multiple drug allergies. Cureus 2020-09-17 /pmc/articles/PMC7571590/ /pubmed/33094048 http://dx.doi.org/10.7759/cureus.10507 Text en Copyright © 2020, Moore et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Moore, Joel
Baer, Maria R
Grover, Brian E
Aster, Richard H
Millstein, Leah S
Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title_full Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title_fullStr Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title_full_unstemmed Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title_short Moxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report
title_sort moxifloxacin-induced thrombocytopenia mediated by moxifloxacin-dependent igm and igg antiplatelet antibodies: a case report
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571590/
https://www.ncbi.nlm.nih.gov/pubmed/33094048
http://dx.doi.org/10.7759/cureus.10507
work_keys_str_mv AT moorejoel moxifloxacininducedthrombocytopeniamediatedbymoxifloxacindependentigmandiggantiplateletantibodiesacasereport
AT baermariar moxifloxacininducedthrombocytopeniamediatedbymoxifloxacindependentigmandiggantiplateletantibodiesacasereport
AT groverbriane moxifloxacininducedthrombocytopeniamediatedbymoxifloxacindependentigmandiggantiplateletantibodiesacasereport
AT asterrichardh moxifloxacininducedthrombocytopeniamediatedbymoxifloxacindependentigmandiggantiplateletantibodiesacasereport
AT millsteinleahs moxifloxacininducedthrombocytopeniamediatedbymoxifloxacindependentigmandiggantiplateletantibodiesacasereport